Outcomes
albuminuria
ADVERSE EVENTS, SECONDARY, REMISSION
The primary endpoint of the ESAX-DN study was the proportion of patients with UACR remission at the end of treatment, and the key secondary endpoint was the percentage change in the UACR from baseline at the end of treatment. The changes in BP and creatinine levels and the rate of transition to overt albuminuria were also assessed. Safety endpoints included adverse events, serum KOf these outcomes, data for the percentage changes in the UACR from baseline to the end of treatment, changes in BP, and changes in eGFR were used in this 